Valeant Pharma (NYSE: VRX) says ex-CEO Mike Pearson is still consulting in 'limited' capacity, according to the company's conference call on Tuesday.

Insiders' Blog

Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook NegativeNovember 8, 2016 2:14 PM Guggenheim Remains Positive on Valeant (VRX) post Q3: 'In the Kitchen Sink, but Not Down the Drain'November 8, 2016 10:35 AM Valeant Pharma (VRX) Sees Solid Bounce Off Morning LowsNovember 8, 2016 10:16 AM Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's RaffatNovember 8, 2016 10:03 AM FDA Posts Valeant Pharma (VRX) Warning Letter Related to Rochester PlantNovember 8, 2016 9:33 AM Valeant Pharma (VRX) Sinks 27% in Pre-Open Trade, Falling Below $14November 8, 2016 8:56 AM Valeant (VRX) Misses, Lowers, Delays - Wells Fargo's MarisNovember 8, 2016 8:33 AM Valeant (VRX) Miss and Guide Down Expected, But Magnitude Maybe Not - MizuhoNovember 8, 2016 8:25 AM Valeant (VRX) Q3 a Mixed Bag, Guidance Cut on Higher Side of Expectations - BMONovember 8, 2016 8:22 AM Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI RaffatNovember 8, 2016 7:53 AM Wall Street gains as traders bet on Clinton triumphNovember 8, 2016 7:20 AM